Induced pluripotent stem cell cardiac therapy

IPS HEART is pioneering a new generation of stem cell therapies aimed at addressing severe medical conditions such as heart disease and Duchenne Muscular Dystrophy (DMD). The company utilizes induced pluripotent stem cells (iPSCs) to create new cardiac and skeletal muscle tissue, which can potentially replace lost or damaged muscle. Their lead therapeutic candidate, ISX9-CPC, combines a small molecule with iPSCs to regenerate cardiac tissue, demonstrating significant improvements in heart function and reductions in scar tissue in preclinical studies. Additionally, their GIVI-MPC therapy aims to provide a more effective treatment for DMD by reprogramming iPSCs to produce full-length dystrophin, a protein essential for muscle function.

The innovative approach of IPS HEART focuses on curing the underlying diseases rather than merely alleviating symptoms, which is a common limitation of current treatments. Their proprietary platform allows for the generation of an unlimited number of new cells from a single master cell line, enabling the potential for durable and safe muscle regeneration. With promising preclinical results and FDA designations, IPS HEART is positioned to advance its therapies into clinical trials, targeting both heart failure and rare muscle diseases, thereby transforming the landscape of treatment for these challenging conditions.

United States

IPS HEART is the first induced pluripotent stem cell company to launch in 2014 around heart disease. With over $20 million+ of funded research, we were the first to publish our moon-shot approach showing extensive heart regeneration after heart attack with over 50%+ EF improvement vs control and a 70% reduction in fibrosis.   We have created extensive new functional human heart muscle in our published studies thus validating our patented IPS small molecule platform approach. With a completed FDA PRE-IND meeting and GMP manufacturing, we plan to file the first IPS IND to start clinically in the United States. 

IPS HEART

Company Details